

19 Jun 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 17 June 2022, including: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?](#)" - Scrip, 13 Jun, 2022.)

(Also see "[BIO 2022 Notebook: Staying Afloat In Rough Waters](#)" - Scrip, 14 Jun, 2022.)

(Also see "[Lilly's Olumiant Is First Drug FDA Approved For Alopecia Areata](#)" - Scrip, 13 Jun, 2022.)

(Also see "[Argenx Enters Japan With Smooth Approval – How Was It Possible?](#)" - Scrip, 10 Jun, 2022.)

(Also see "[BTK Inhibitors Are The Next Big Race In MS](#)" - Scrip, 9 Jun, 2022.)

[Click here to explore this interactive content online](#) 